Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week Low - Here's Why

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $555.30 and last traded at $559.72, with a volume of 465172 shares traded. The stock had previously closed at $572.78.

Analysts Set New Price Targets

A number of research analysts have recently commented on REGN shares. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Finally, Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Trading Up 1.4 %

The company has a market cap of $60.59 billion, a PE ratio of 14.48, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a 50 day simple moving average of $659.94 and a two-hundred day simple moving average of $755.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.